earnings
confidence high
sentiment positive
materiality 0.70
Quince Therapeutics Q3 net loss $13.3M; Phase 3 NEAT trial on track for Q1 2026 data
Quince Therapeutics, Inc.
2025-Q3 EPS reported
-$0.92
- Cash, cash equivalents, and short-term investments of $26.3M; runway expected through Q2 2026.
- Phase 3 NEAT enrollment completed (105 participants); topline results expected first quarter 2026.
- iDSMB recommended study continue without modifications; 100% of patients chose open-label extension.
- Net loss $13.3M ($0.25/sh); R&D expenses $8.1M, G&A expenses $3.3M for Q3 2025.
- FDA Fast Track designation; NDA submission planned H2 2026 assuming positive study results.